MRI-based radiomic signatures for pretreatment prognostication in cervical cancer.

BACKGROUND

Accurate pretherapeutic prognostication is important for tailoring treatment in cervical cancer (CC).

PURPOSE

To investigate whether pretreatment MRI-based radiomic signatures predict disease-specific survival (DSS) in CC.

STUDY TYPE

Retrospective.

POPULATION

CC patients (n = 133) allocated into training (n  = 89)/validation (n  = 44) cohorts.

FIELD STRENGTH/SEQUENCE: T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI) at 1.5T or 3.0T.

ASSESSMENT

Radiomic features from segmented tumors were extracted from T2WI and DWI (high b-value DWI and apparent diffusion coefficient (ADC) maps).

STATISTICAL TESTS

Radiomic signatures for prediction of DSS from T2WI (T2 ) and T2WI with DWI (T2 + DWI ) were constructed by least absolute shrinkage and selection operator (LASSO) Cox regression. Area under time-dependent receiver operating characteristics curves (AUC) were used to evaluate and compare the prognostic performance of the radiomic signatures, MRI-derived maximum tumor size ≤/> 4 cm (MAX ), and 2018 International Federation of Gynecology and Obstetrics (FIGO) stage (I-II/III-IV). Survival was analyzed using Cox model estimating hazard ratios (HR) and Kaplan-Meier method with log-rank tests.

RESULTS

The radiomic signatures T2 and T2 + DWI yielded AUC /AUC of 0.80/0.62 and 0.81/0.75, respectively, for predicting 5-year DSS. Both signatures yielded better or equal prognostic performance to that of MAX (AUC /AUC : 0.69/0.65) and FIGO (AUC /AUC : 0.77/0.64) and were significant predictors of DSS after adjusting for FIGO (HR /HR for T2 : 4.0/2.5 and T2 + DWI : 4.8/2.1). Adding T2 and T2 + DWI to FIGO significantly improved DSS prediction compared to FIGO alone in cohort (AUC 0.86 and 0.88 vs. 0.77), and FIGO with T2 + DWI tended to the same in cohort (AUC 0.75 vs. 0.64, p = 0.07). High radiomic score for T2 + DWI was significantly associated with reduced DSS in both cohorts.

DATA CONCLUSION

Radiomic signatures from T2WI and T2WI with DWI may provide added value for pretreatment risk assessment and for guiding tailored treatment strategies in CC.